EcoDrugPlus

Neuropeptide Y Receptor Y2

Ensembl ID : ENSPKIG00000015322
Gene Symbol: NPY2R
3 Cross references
246 Possible Orthologues:

Neuropeptide Y Receptor Y4-2

Ensembl ID : ENSPKIG00000011037
Gene Symbol: NPY4R2
2 Cross references
116 Possible Orthologues:

Neuropeptide Y Receptor Y5

Ensembl ID : ENSPKIG00000019730
Gene Symbol: NPY5R
4 Cross references
135 Possible Orthologues:

Neurotensin Receptor 1

Ensembl ID : ENSPKIG00000018093
Gene Symbol: NTSR1
4 Cross references
137 Possible Orthologues:

Neurotensin Receptor 1

Ensembl ID : ENSPKIG00000006216
Gene Symbol: NTSR1
3 Cross references
203 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSPKIG00000021781
Gene Symbol: NTRK2
1 Cross references
209 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSPKIG00000014190
Gene Symbol: NTRK3
1 Cross references
203 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSPKIG00000019993
Gene Symbol: NTRK3
4 Cross references
203 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 1

Ensembl ID : ENSPKIG00000009512
Gene Symbol: NTRK1
1 Cross references
197 Possible Orthologues:

Nicastrin

Ensembl ID : ENSPKIG00000007630
Gene Symbol: NCSTN
4 Cross references
203 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSPKIG00000017062
Gene Symbol: NAMPT
4 Cross references
223 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSPKIG00000016179
Gene Symbol: NAMPT
2 Cross references
223 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).